XML 35 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and intangible assets GOODWILL AND INTANGIBLE ASSETS
    
Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
CSCA(1)
CSCI(2)
Total
Balance at December 31, 2019$1,899.1 $1,203.7 $3,102.8 
Business divestitures— (115.6)(115.6)
Business acquisitions14.8 7.3 22.1 
Currency translation adjustments1.5 83.3 84.8 
Purchase accounting adjustments(10.4)12.0 1.6 
Balance at December 31, 20201,905.0 1,190.7 3,095.7 
Impairments(6.1)(10.0)(16.1)
Purchase accounting adjustments 2.4 (2.4)— 
Currency translation adjustments1.1 (81.3)(80.2)
Balance at December 31, 2021$1,902.4 $1,097.0 $2,999.4 

(1) We had accumulated goodwill impairments of $6.1 as of December 31, 2021.
(2) We had accumulated goodwill impairments of $878.4 as of December 31, 2021 and $868.4 million as of December 31, 2020.


CSCA Reporting Unit Goodwill

On May 18, 2021, we announced a definitive agreement to sell our Mexico and Brazil-based OTC businesses ("Latin American businesses"), both within our CSCA segment, to Advent International. As a result, we prepared a goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment of $6.1 million within our CSCA segment during the three months ended July 3, 2021 (refer to Note 7 and Note 9).

CSCI Reporting Unit Goodwill

During the three months ended December 31, 2021, we reorganized the reporting structure within our CSCI segment following the integration of our reporting units into a new operating structure. The goodwill previously included in the Oral Care International, CSC UK and Australia, and BCS reporting units was combined into a single CSCI reporting unit. Impairment tests were performed for the legacy reporting units prior to the reorganization and for the CSCI reporting unit immediately after the reorganization.

During the three months ended June 27, 2020, our Branded Consumer Self-care ("BCS") reporting unit included in the CSCI segment had an indication of potential impairment which was driven by a decrease in forecasted cash flows in the second half of 2020 related to impacts from the COVID-19 pandemic. We prepared an impairment test as of June 27, 2020 and determined that the fair value of the BCS reporting unit exceeded net book value by less than 10%, consistent with prior annual impairment test as of October 1, 2019. There was no indication of impairment during the remaining six months of December 31, 2020, nor during the year ended December 31, 2021.

In conjunction with our annual impairment test, during the three months ended December 31, 2021, we recorded an impairment charge in our Oral Care International reporting unit within our CSCI segment of $10.0 million. The change in fair value from previous estimates was driven by reduced projections of future cash flows resulting from increased costs throughout the global supply chain (refer to Note 7).
Intangible assets and the related accumulated amortization consisted of the following (in millions):
Year Ended
 December 31, 2021December 31, 2020
 GrossAccumulated
Amortization		GrossAccumulated
Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands$3.5 $— $4.3 $— 
In-process research and development1.8 — 2.7 — 
Total indefinite-lived intangibles$5.3 $— $7.0 $— 
Definite-lived intangibles:
Distribution and license agreements and supply agreements$73.2 $56.9 $74.8 $55.4 
Developed product technology, formulations, and product rights300.2 191.4 303.3 177.3 
Customer relationships and distribution networks1,820.7 887.8 1,920.5 823.7 
Trademarks, trade names, and brands1,482.3 394.2 1,581.5 342.2 
Non-compete agreements2.1 2.1 2.9 2.9 
Total definite-lived intangibles$3,678.5 $1,532.4 $3,883.0 $1,401.5 
Total intangible assets$3,683.8 $1,532.4 $3,890.0 $1,401.5 
Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.

The remaining weighted-average useful life for our amortizable intangible assets by asset class at December 31, 2021 was as follows:
Amortizable Intangible Asset CategoryRemaining Weighted-Average Useful Life (Years)
Distribution and license agreements and supply agreements7
Developed product technology, formulations, and product rights8
Customer relationships and distribution networks15
Trademarks, trade names, and brands15

We recorded amortization expense of $210.0 million, $212.2 million, and $219.6 million during the years ended December 31, 2021, December 31, 2020, and December 31, 2019, respectively.

    Our estimated future amortization expense is as follows (in millions):
YearAmount
2022$194.9 
2023183.6 
2024174.7 
2025168.0 
2026160.2 
Thereafter1,264.7 

Licensed Pain Relief Products

During the year ended December 31, 2019, following commercial launch delays relating to certain pain relief products that we licensed from a third party, the licensor determined that it would not extend the license agreement upon expiration. As a result, we determined the asset was fully impaired and recorded an asset
impairment of $9.7 million relating to this license, which we had reported as a definite-lived intangible asset in our CSCI segment (refer to Note 7).

In-process R&D ("IPR&D")

We recorded an impairment charge of $0.9 million and $4.1 million on certain IPR&D assets during the years ended December 31, 2021 and December 31, 2019, respectively, due to changes in the projected development and regulatory timelines for various projects.